Results 61 to 70 of about 506,875 (293)

Radiofrequency Catheter Ablation of Atrioventricular Nodal Reentrant Tachycardia: It Is Not Always As It Is Expected [PDF]

, 2004
Observation of Coincident arrhythmias is not uncommon but the co-existence of idiopathic verapamil sensitive left ventricular tachycardia (ILVT) with other arrhythmias is very rare.
Heydari, Alireza, Emkanjoo, Zahra, Arash Arya, Sadr-Ameli, Mohammad Ali, Zahra Emkanjoo, Mohammad Ali Sadr-Ameli, Alireza Heydari, Haghjoo, Majid, Arya, Arash, Majid Haghjoo   +9 more
core  

Imaging-guided Ventricular Tachycardia Ablation [PDF]

Arrhythmia & Electrophysiology Review, 2013
Over the past decades important advances have been made in the field of ventricular tachycardia (VT) ablation, and as a result, VT ablation is now more widely being performed. The identification of ablation target sites still relies on electroanatomical substrate mapping, which is time-consuming, hampered by the intramural location of some scars and ...
Sebastiaan Rd, Piers, Katja, Zeppenfeld
openaire   +2 more sources

Idiopathic Ventricular Tachycardia: Transcatheter Ablation or Antiarrhythmic Drugs? [PDF]

, 2015
INTRODUCTION: Ventricular tachycardia or frequent premature ventricular contractions (PVCs) can occur in the absence of any detectable structural heart disease. In this clinical setting, these arrhythmias are termed idiopathic.
Russo, Eleonora, Pizzamiglio, Francesca, Zucchetti, Martina, Cattaneo, Fabio, Carbucicchio, Corrado, Tondo, Claudio, Bologna, Fabrizio, Casella, Michela, Colombo, Daniele, F. Pizzamiglio, D. Colombo, Dello Russo, Antonio, C. Tondo, Russo, Antonio Dello, B. Majocchi, Majocchi, Benedetta, F. Cattaneo, M. Zucchetti   +17 more
core   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Catheter ablation of common atrioventricular nodal reentry tachycardia using the conventional method

Zanco Journal of Medical Sciences, 2019
Background and objective: Atrioventricular nodal reentry tachycardia is the commonest type of supraventricular tachycardia referred to the electrophysiology laboratory.
Amar Alhamdi
doaj  

“From Surface to Substrate: Advancing VT Ablation Strategies for Deep Arrhythmic Substrates”—A Review of Emerging Techniques in Intramural Lesion Formation

Reviews in Cardiovascular Medicine
Intramural ventricular tachycardia represents a formidable frontier in catheter ablation, where the arrhythmogenic substrate resides deep within the myocardial wall, often beyond the reach of conventional energy delivery.
Krittapoom Akrawinthawong, Roopesh Sai Jakulla, Takumi Yamada   +2 more
doaj   +1 more source

Ventricular Tachycardia in the Absence of Structural Heart Disease [PDF]

, 2005
In up to 10% of patients who present with ventricular tachycardia (VT), obvious structural heart disease is not identified. In such patients, causes of ventricular arrhythmia include right ventricular outflow tract (RVOT) VT, extrasystoles, idiopathic ...
Scott, Luis R P, Lester, Steven J, Munger, Thomas M, Appleton, Christopher P, Srivathsan, Komandoor   +4 more
core  

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Ventricular Tachycardia Ablation

JACC: Clinical Electrophysiology, 2019
Ventricular tachycardia (VT) ablation can in many cases be one of the most challenging areas of invasive electrophysiology. Reducing symptoms associated with VT and reducing the morbidity associated with ICD shocks remain the most common indications for VT ablation.
Neil T. Srinivasan, Alex Cambridge
openaire   +2 more sources

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source